Industry news
-
Pfizer's tafamidis wins blockbuster nod—and gets a lower price—to rival Alnylam, Ionis
07 May 2019
Once rejected by the FDA, Pfizer’s tafamidis is back and ready to disrupt a rare disease field only recently tapped by Alnylam and Ionis. And the pharma giant's entrant, now dubbed Vyndaqel, comes with a much lower price tag.
-
EMA Launches Social Media Campaign on Medicines Regulation in EU
07 May 2019
EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines available in Europe safe and effective. As of today, EMA will start sharing a series of info-cards on its Twitter and LinkedIn accounts.
-
Russian Companies to Scale Up Production of Innovative HIV Drug
06 May 2019
Pharmstandard, the leader of the Russian pharmaceutical market, and ChemRar Group, the leading developer of medical products, have combined their efforts to scale up the production of Elpida®, a Russian innovative antiviral drug for the treatment of HIV infection.
-
06 May 2019
Higher prescription drugs sales and restrained spending together gave drugmaker Pfizer a 9% jump in first quarter profit as it easily topped analysts’ profit expectations. Sales of breast cancer drug Ibrance and blood thinner Eliquis both jumped over 20% to more than $1 billion each in the quarter, and Xeljanz for rheumatoid arthritis saw sales soar 30%, lifting prescription drug sales by 3%.
-
If pharma looks slow to adopt AI, it's got good reason, expert says
06 May 2019
Pharma hasn’t exactly won accolades for its speed in adopting new artificial intelligence and machine learning technologies. But while it’s drawn flak for that digital lag, it’s got good reason to proceed with caution where AI is concerned, one expert says.
-
Pharmaceutical Companies Reported Strong Q1 Growth of Oncology Drugs Sales
30 April 2019
Pharmaceutical companies have reported strong Q1 growth by their oncology drugs, based on earnings reports from Johnson & Johnson, Bristol-Myers Squibb, Bayer, Novartis and AbbVie.
-
FDA Announced the Launch of a New Education Campaign
30 April 2019
The U.S. Food and Drug Administration today announced the launch of a new education campaign to help Americans understand the important role they play in removing and properly disposing of unused prescription opioids from their homes. This new initiative is part of the FDA’s continued efforts to address the nationwide opioid crisis and aims to help decrease unnecessary exposure to opioids and prevent new addiction.
-
Transparency Market Research Expects Orphan Drugs Market to Grow 12% per Year
29 April 2019
TMR’s experts’ projection states that the global orphan drugs market is prophesized to grow at a meteoric 12.10% CAGR during the assessment period 2017-2025. The market is anticipated to gain a net value of US$318.5 bn by the end of the forecast period.
-
Russia’s Pharma Market Grew by 1,7% in Q1 2019
29 April 2019
The Russian pharmaceutical market continues to see growth. Over the first three months of this year, it grew by 1.7% in ruble terms and reached 255.2 billion rubles, stated DSM Group in its analytical report published in March 2019.
-
First Results of EAEU Member Countries’ Pharmaceutical Inspectorates Cooperation
26 April 2019
Not only pharmaceutical companies of the EAEU member countries are reaching after obtaining an EAEU GMP certificate – the process is starting to involve foreign pharmaceutical manufacturers as well. This was brought to light by the Director of SID & GP Mr. Vladislav Shestakov at the “RegLec – EAEU” conference.
